Bristol Myers Squibb Says It Has Received Positive Chmp Opinion For Car T Cell Therapy Abecma (idecabtagene vicleucel) In Earlier Lines Of Therapy For Triple-class Exposed Relapsed And Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its CAR T cell therapy Abecma (idecabtagene vicleucel) for use in earlier lines of therapy for patients with triple-class exposed relapsed and refractory multiple myeloma.
January 26, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's CAR T cell therapy Abecma has received a positive CHMP opinion, potentially expanding its use in the treatment of multiple myeloma.
The positive opinion from CHMP is a significant regulatory milestone for Bristol Myers Squibb, likely leading to increased adoption and sales of Abecma. This could have a favorable impact on the company's stock price in the short term as it reflects the potential for growth in the drug's market share and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100